Relapse patterns and outcome after relapse in standard risk medulloblastoma: a report from the HIT-SIOP-PNET4 study.

PubWeight™: 0.75‹?›

🔗 View Article (PMID 27423645)

Published in J Neurooncol on July 16, 2016

Authors

Magnus Sabel1, Gudrun Fleischhack2, Stephan Tippelt2, Göran Gustafsson3, François Doz4, Rolf Kortmann5, Maura Massimino6, Aurora Navajas7, Katja von Hoff8, Stefan Rutkowski8, Monika Warmuth-Metz9, Steven C Clifford10, Torsten Pietsch11, Barry Pizer12, Birgitta Lannering13, SIOP-E Brain Tumour Group

Author Affiliations

1: Department of Paediatrics, University of Gothenburg and Queen Silvia Children's Hospital, Gothenburg, Sweden. magnus.sabel@vgregion.se.
2: Paediatrics III, Division of Paediatric Haematology and Oncology, University Hospital of Essen, Essen, Germany.
3: Karolinska Institutet, Stockholm, Sweden.
4: Department of Paediatrics, Adolescent and Young Adults Oncology, Institut Curie and University Paris Descartes, Sorbonne Paris Cité, Paris, France.
5: Department of Radiooncology, University Hospital Leipzig, Leipzig, Germany.
6: Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
7: Biocruces Health Research Institute, Universidad Del País Vasco/EHU, Bilbao, Spain.
8: University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.
9: University of Würzburg, Würzburg, Germany.
10: Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK.
11: Department of Neuropathology, University of Bonn, Bonn, Germany.
12: Alder Hey Children's Hospital, Liverpool, UK.
13: Department of Paediatrics, University of Gothenburg and Queen Silvia Children's Hospital, Gothenburg, Sweden.

Articles cited by this

Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol (2006) 4.72

beta-Catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour Committee. J Clin Oncol (2005) 2.84

Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. Lancet Oncol (2013) 2.82

Surveillance scanning of children with medulloblastoma. N Engl J Med (1994) 2.47

Hyperfractionated versus conventional radiotherapy followed by chemotherapy in standard-risk medulloblastoma: results from the randomized multicenter HIT-SIOP PNET 4 trial. J Clin Oncol (2012) 2.01

MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma. Acta Neuropathol (2011) 1.33

Survival and secondary tumors in children with medulloblastoma receiving radiotherapy and adjuvant chemotherapy: results of Children's Oncology Group trial A9961. Neuro Oncol (2012) 1.20

High-dose chemotherapy with autologous stem-cell rescue in patients with recurrent and high-risk pediatric brain tumors. J Clin Oncol (1997) 1.14

Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable disease. Cancer Cell (2014) 1.08

Antiangiogenic metronomic therapy for children with recurrent embryonal brain tumors. Pediatr Blood Cancer (2011) 1.00

Medulloblastoma subgroups remain stable across primary and metastatic compartments. Acta Neuropathol (2015) 1.00

Efficacy of high-dose chemotherapy or standard salvage therapy in patients with recurrent medulloblastoma. Neuro Oncol (2008) 0.96

Treatment of recurrent central nervous system primitive neuroectodermal tumours in children and adolescents: results of a Children's Cancer and Leukaemia Group study. Eur J Cancer (2011) 0.95

Surveillance neuroimaging of intracranial medulloblastoma in children: how effective, how often, and for how long? J Neurosurg (2003) 0.94

Improving survival in recurrent medulloblastoma: earlier detection, better treatment or still an impasse? Br J Cancer (1998) 0.87

No salvage using high-dose chemotherapy plus/minus reirradiation for relapsing previously irradiated medulloblastoma. Int J Radiat Oncol Biol Phys (2008) 0.87

Second complete remission of relapsed medulloblastoma induced by metronomic chemotherapy. Pediatr Blood Cancer (2010) 0.85

Temozolomide is an active agent in children with recurrent medulloblastoma/primitive neuroectodermal tumor: an Italian multi-institutional phase II trial. Neuro Oncol (2014) 0.84

Biomarker-driven stratification of disease-risk in non-metastatic medulloblastoma: Results from the multi-center HIT-SIOP-PNET4 clinical trial. Oncotarget (2015) 0.80

Reirradiation of recurrent medulloblastoma: does clinical benefit outweigh risk for toxicity? Cancer (2014) 0.80

Role of spinal MRI in the follow-up of children treated for medulloblastoma. Cancer (2006) 0.79

Treatment of recurrent primitive neuroectodermal tumors (PNET) in children and adolescents with high-dose chemotherapy (HDC) and stem cell support: results of the HITREZ 97 multicentre trial. J Neurooncol (2014) 0.78